{
"id":"mk19_a_id_s9",
"subspecialtyId":"id",
"title":"Sexually Transmitted Infections",
"jsonContent":{
"type":"section",
"id":"mk19_a_id_s9",
"title":{
"__html":"Sexually Transmitted Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"81b545",
"children":[
"Sexually Transmitted Infections"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s9_1",
"title":{
"__html":"Introduction"
},
"titleNode":{
"type":"section-title",
"hlId":"0b7979",
"children":[
"Introduction"
]
},
"children":[
{
"type":"p",
"hlId":"29b739",
"children":[
"Sexually transmitted infections (STIs) occur most commonly in adolescents, young adults, and men who have sex with men (MSM). Most infections are asymptomatic, so a detailed sexual history, including sexual practices, is imperative to understanding individual risk. STI risk factors include a new partner, more than one current partner, a partner with an STI, or a partner who has concurrent partners. Particularly high-risk populations include persons attending STI clinics and MSM. The U.S. Preventive Services Task Force (USPSTF) recommends behavioral counseling to reduce the likelihood of acquiring STIs in sexually active adolescents and in adults at increased risk."
]
},
{
"type":"p",
"hlId":"e1439a",
"children":[
"Unrecognized or inadequately treated STIs are a preventable cause of infertility in women. The World Health Organization and the CDC provide evidence-based guidelines for the evaluation and management of STIs; the CDC guidelines are recommended for use in the United States. Any patient diagnosed with an STI should be evaluated for other STIs, including HIV, and receive risk reduction counseling."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_2",
"title":{
"__html":"<i>Chlamydia trachomatis</i> Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"6e3ae4",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
},
" Infection"
]
},
"children":[
{
"type":"p",
"hlId":"6e21e1",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
},
" is the most commonly reported bacterial STI in the United States. Screening of all sexually active women younger than 25 years is recommended. Women aged 25 years and older should be screened if they have STI risk factors. The USPSTF concluded that evidence is insufficient to support routine screening in men; the CDC recommends screening men in settings or populations with high prevalence or burden of disease (MSM, STI clinics)."
]
},
{
"type":"p",
"hlId":"3f5cc9",
"children":[
"Nucleic acid amplification testing (NAAT) is preferred for screening and diagnosis. First-catch urine (for men and women) and endocervical (for women) or urethral (for men) swabs can be used. NAAT of urine samples for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" has been shown to have a sensitivity and specificity nearly identical to tests obtained from urethral and endocervical samples. Chlamydia may cause oropharyngeal and rectal infection, and these sites should be evaluated using NAAT; MSM should be screened yearly for urethral and rectal infection."
]
},
{
"type":"p",
"hlId":"101d0c",
"children":[
"Treatment of clinical syndromes caused by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t30",
"wrapId":"1",
"children":[
"Table 30"
]
}
]
},
". Test of cure is not recommended, except in pregnancy. Because of the high risk of repeat infection, men and women should be retested after 3 months or the next time they are seen for medical care."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_a_id_t30"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"0ecc88",
"children":[
"Nucleic acid amplification testing is the preferred screening and diagnostic method for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
},
" infection."
]
},
{
"type":"keypoint",
"hlId":"527d29",
"hvc":true,
"children":[
"Test of cure is not recommended in patients with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
},
" infection except in pregnancy; however, patients should be retested for possible repeat infection after 3 months or at their next medical visit."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_3",
"title":{
"__html":"<i>Neisseria gonorrhoeae</i> Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"4b2b02",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" Infection"
]
},
"children":[
{
"type":"p",
"hlId":"d1360f",
"children":[
"Persons aged 20 to 24 years are at highest risk for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" infection. In addition to cervicitis, urethritis, pharyngitis, and rectal infection, disseminated gonococcal infection (presenting as arthritis-dermatitis syndrome) can occur (see ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s13_2_2_1",
"children":[
"MKSAP 19 Rheumatology"
]
},
"). Infection can be asymptomatic, especially in women, so screening is recommended for women younger than 25 years and those 25 years and older with STI risk factors. The USPSTF does not recommend screening for men; the CDC recommends screening men at high risk, as for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
"."
]
},
{
"type":"p",
"hlId":"694f1c",
"children":[
"For screening and diagnosis, NAAT is preferred. Men and women can be screened using a first-catch urine sample; endocervical, urethral, rectal, and pharyngeal swabs may also be used. Pharyngeal, urethral and rectal sites should be tested at least yearly in MSM. In patients with disseminated gonococcal infection, all ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" isolates should be tested for antimicrobial susceptibility. Patients with suspected disseminated gonococcal infection should have cultures performed on blood, joint fluid (if arthritis is present), purulent skin lesions (if present), and cerebrospinal fluid (if meningitis is suspected); however, culture yield is not high, so NAAT from all potential sites of exposure (genital, pharyngeal, rectal) should be obtained."
]
},
{
"type":"p",
"hlId":"f30705",
"children":[
"Treatment is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t30",
"wrapId":"2",
"children":[
"Table 30"
]
}
]
},
". For uncomplicated gonococcal infections of the cervix, urethra, or rectum, ceftriaxone monotherapy is recommended because ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" remains susceptible to ceftriaxone, and azithromycin resistance is increasing; the recommended ceftriaxone dose has increased. In patients with an allergy precluding use of cephalosporins, oral gemifloxacin or parenteral gentamicin plus oral azithromycin is an option."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_a_id_t30"
]
},
{
"type":"p",
"hlId":"02a170",
"children":[
"Patients with infections caused by ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" who do not respond to treatment should have repeat testing with NAAT and culture so that susceptibility data can be obtained; consultation with an expert in nonresponsive infections is advised."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e1ce89",
"children":[
"Screening for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" infection is recommended for women younger than 25 years and those 25 years and older with risk factors (new partner, more than one partner, a partner with an STI, or a partner who has concurrent partners)."
]
},
{
"type":"keypoint",
"hlId":"9511d4",
"children":[
"Nucleic acid amplification testing is the preferred screening and diagnostic method for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" infection."
]
},
{
"type":"keypoint",
"hlId":"1b84c3",
"children":[
"Parenteral ceftriaxone is the preferred regimen for the treatment of uncomplicated ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" infection."
]
},
{
"type":"keypoint",
"hlId":"de49a8",
"children":[
"Test of cure in patients with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" infection is recommended 2 weeks after therapy only when pharyngeal gonorrhea is treated with an alternate antibiotic regimen."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_4",
"title":{
"__html":"<i>Mycoplasma genitalium</i> Infection"
},
"titleNode":{
"type":"section-title",
"hlId":"4c5374",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Mycoplasma genitalium"
]
},
" Infection"
]
},
"children":[
{
"type":"p",
"hlId":"8b700a",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. genitalium"
]
},
" is an emerging STI that is a cause of urethritis in men. It has been reported to cause up to 20% of nongonococcal urethritis and 46% of nongonococcal/nonchlamydial urethritis in men. As an STI pathogen in women, it is implicated in cervicitis and pelvic inflammatory disease (PID). The optimal role for testing with NAAT in clinical practice has yet to be defined, and no recommendations have been published for routine screening. Recommended treatment for nongonococcal urethritis is azithromycin (1-g single dose); however, azithromycin resistance is increasingly reported, and a longer course or alternate therapy may be required."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_5",
"title":{
"__html":"Clinical Syndromes"
},
"titleNode":{
"type":"section-title",
"hlId":"5953d4",
"children":[
"Clinical Syndromes"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s9_5_1",
"title":{
"__html":"Cervicitis"
},
"titleNode":{
"type":"section-title",
"hlId":"fed385",
"children":[
"Cervicitis"
]
},
"children":[
{
"type":"p",
"hlId":"597614",
"children":[
"Women with cervicitis may have vaginal discharge and intermenstrual bleeding, but many are asymptomatic. The major diagnostic criteria are visualization of mucopurulent discharge from the cervical os or on a swab obtained from the endocervical canal and eliciting bleeding by passing a swab into the cervical os. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" are the most commonly isolated pathogens; however, many cases are enigmatic. The role of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. genitalium"
]
},
" is still unclear; herpes simplex virus is occasionally implicated. Noninfectious causes (for example, chemical irritation from douching) should be sought. Patients should be tested for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" with NAAT, as well as being evaluated for bacterial vaginosis and trichomoniasis (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s7_7",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
")."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_5_2",
"title":{
"__html":"Pelvic Inflammatory Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"d33497",
"children":[
"Pelvic Inflammatory Disease"
]
},
"children":[
{
"type":"p",
"hlId":"4be337",
"children":[
"Unrecognized PID may result in long-term sequelae, including infertility, chronic pelvic pain, and ectopic pregnancy. Symptoms include lower abdominal pain, vaginal discharge, intermenstrual bleeding or bleeding after intercourse, and dyspareunia. Some women have fever and other signs of systemic toxicity, but this is uncommon."
]
},
{
"type":"p",
"hlId":"2cc420",
"children":[
"The presence of uterine tenderness, adnexal tenderness, or cervical motion tenderness is sufficient to make a clinical diagnosis of PID, especially if accompanied by mucopurulent cervical discharge."
]
},
{
"type":"p",
"hlId":"0717a6",
"children":[
"PID is believed to be polymicrobial; however, testing is only indicated for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
". Most infections can be managed in the ambulatory setting with oral antibiotics (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t30",
"wrapId":"3",
"children":[
"Table 30"
]
}
]
},
")"
]
},
". Indications for hospitalization include inability to exclude a surgical emergency such as appendicitis, pregnancy, severe systemic toxicity, tubo-ovarian abscess, inability to tolerate oral antibiotics, and failure of initial outpatient management."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_a_id_t30"
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_5_3",
"title":{
"__html":"Urethritis"
},
"titleNode":{
"type":"section-title",
"hlId":"99932d",
"children":[
"Urethritis"
]
},
"children":[
{
"type":"p",
"hlId":"38372a",
"children":[
"Men with urethritis present with dysuria, urethral pruritus, and clinically diagnostic mucopurulent discharge. ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
", and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. genitalium"
]
},
" are common causes; ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Trichomonas"
]
},
" may also be causative. A first-catch urine sample should be tested for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" by NAAT; an FDA-approved NAAT for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"M. genitalium"
]
},
" is available. Microscopic examination of a urethral sample that reveals more than 2 leukocytes per high-powered field has a high positive predictive value for infectious urethritis, but the negative predictive value is poor. A positive leukocyte esterase test result or a microscopic examination with 10 or more leukocytes on a first-void urine specimen is also diagnostic for infectious urethritis. This testing is not required if mucoid, mucopurulent, or purulent urethral discharge is demonstrated on examination."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_5_4",
"title":{
"__html":"Epididymitis"
},
"titleNode":{
"type":"section-title",
"hlId":"f6aace",
"children":[
"Epididymitis"
]
},
"children":[
{
"type":"p",
"hlId":"708f64",
"children":[
"Men with epididymitis present with unilateral pain and swelling in the epididymis; the testes may also be inflamed (epididymo-orchitis). ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" are likely causes in younger, sexually active men. Older men and men who practice insertive anal intercourse may be infected with enteric gram-negative organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Escherichia coli."
]
},
" NAAT for STI pathogens should be performed on first-catch urine, and a urine culture should be obtained. See ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s6_5",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
" for further information."
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_5_5",
"title":{
"__html":"Anorectal Infections"
},
"titleNode":{
"type":"section-title",
"hlId":"238a56",
"children":[
"Anorectal Infections"
]
},
"children":[
{
"type":"p",
"hlId":"8db415",
"children":[
"Patients who present with anorectal pain, rectal discharge, or tenesmus should be questioned regarding sexual practices. In addition to receptive anal intercourse, infection may occur in women because of autoinoculation from vaginal discharge. Causes include ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
", syphilis, and herpes simplex virus (HSV). Infections caused by lymphogranuloma venereum (LGV) serovars (L1, L2, or L3) of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" are an increasing cause of proctitis and proctocolitis."
]
},
{
"type":"p",
"hlId":"9395f9",
"children":[
"Diagnostic evaluation should include NAAT for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
", and HSV as well as serologic testing for syphilis. Additional molecular testing is required to identify LGV serovars of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
", but it is not widely available commercially; LGV serovars of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" will be detected by currently available NAATs."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"339fa7",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" are the primary causative organisms in cervicitis, pelvic inflammatory disease, urethritis, epididymitis, and anorectal infections, although other organisms may also be implicated."
]
},
{
"type":"keypoint",
"hlId":"2d1e7f",
"children":[
"The two major diagnostic criteria of cervicitis are visualization of mucopurulent discharge from the cervical os or on a swab obtained from the endocervical canal or eliciting bleeding by passing a swab into the cervical os."
]
},
{
"type":"keypoint",
"hlId":"c932d0",
"children":[
"The presence of uterine tenderness, adnexal tenderness, or cervical motion tenderness is sufficient to make a clinical diagnosis of pelvic inflammatory disease, especially if accompanied by mucopurulent cervical discharge."
]
},
{
"type":"keypoint",
"hlId":"e60a2c",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
},
" are likely causes of epididymitis in younger, sexually active men; older men and men who practice insertive anal intercourse may be infected with enteric gram-negative organisms such as ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Escherichia coli."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_5_6",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"2e3bd8",
"children":[
"Treatment of the clinical syndromes discussed previously is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t30",
"wrapId":"4",
"children":[
"Table 30"
]
}
]
},
". Symptomatic patients evaluated in urgent care centers or emergency departments and others who may not be able to return for follow up should be treated empirically based on clinical syndrome. Diagnostic testing should still be obtained because STIs are reportable, and test results will be informative if the infection fails to respond to empiric therapy."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_a_id_t30"
]
},
{
"type":"p",
"hlId":"98d0f6",
"children":[
"Patients should abstain from sexual contact until 7 days after completion of therapy and all sexual partners have been treated. Sexual partners in the previous 60 days, or the most recent partner if greater than 60 days, should be referred for evaluation and treatment. Although independent evaluation and testing of sexual partners is preferred, most states have provisions for providing empiric antibiotic therapy prescriptions to the patient for their partners (expedited partner therapy, or EPT)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"6c9cc7",
"children":[
"Most states have provisions for providing empiric antibiotic therapy prescriptions for sexual partners (expedited partner therapy)."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_6",
"title":{
"__html":"Genital Ulcers"
},
"titleNode":{
"type":"section-title",
"hlId":"cdb1f5",
"children":[
"Genital Ulcers"
]
},
"children":[
{
"type":"section",
"id":"mk19_a_id_s9_6_1",
"title":{
"__html":"Herpes Simplex Virus"
},
"titleNode":{
"type":"section-title",
"hlId":"21bae8",
"children":[
"Herpes Simplex Virus"
]
},
"children":[
{
"type":"p",
"hlId":"118370",
"children":[
"In some populations, such as young heterosexual women and MSM, HSV-1 is now a more common cause of symptomatic primary infection than HSV-2. HSV-1 is less likely than HSV-2 to cause symptomatic recurrent ulcers and subclinical shedding. Differentiation between the two viral subtypes is important in counseling patients regarding the natural history of their infection."
]
},
{
"type":"p",
"hlId":"479ef9",
"children":[
"Primary infection presents as multiple painful lesions that begin as erythematous papules, progress to vesicles, then ulcerate, crust, and eventually heal within 2 to 3 weeks ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f21",
"wrapId":"5",
"children":[
"Figure 21"
]
}
]
},
")"
]
},
". Primary infection is often accompanied by significant systemic symptoms. Tender inguinal lymphadenopathy may be present."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_a_id_f21"
]
},
{
"type":"p",
"hlId":"321661",
"children":[
"NAAT for HSV-1 and HSV-2 using a swab obtained from the ulcer base is preferred to confirm the diagnosis. Type-specific serologic testing is not advised for diagnosing symptomatic ulcer disease because patients can be seropositive for HSV-1 or HSV-2 yet have genital ulcers from another cause. Serologic testing may be performed when evaluating the potential benefits of long-term suppressive therapy to decrease the transmission risk in serodiscordant couples. The CDC recommends considering HSV serologic testing in persons who present for STI evaluation, MSM, and persons with HIV infection. Serologic screening in the general population is not recommended."
]
},
{
"type":"p",
"hlId":"81fd55",
"children":[
"Antiviral therapy for primary infection has been shown to decrease time to resolution of symptoms, lesion healing, and viral shedding ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t31",
"wrapId":"6",
"children":[
"Table 31"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_a_id_t31"
]
},
{
"type":"p",
"hlId":"dc8726",
"children":[
"Recurrent genital HSV infections are less severe. Many patients will experience prodromal itching, burning, or tingling before ulcers appear. Atypical presentations such as fissures and excoriations may occur. Recurrent infection can be managed with either episodic self-start therapy (initiated within 24 hours of symptoms) or long-term suppressive therapy (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t31",
"wrapId":"7",
"children":[
"Table 31"
]
}
]
},
")"
]
},
". Long-term suppressive therapy should be considered for persons with frequent recurrences and should be discussed with all patients because this strategy can decrease the risk of transmission to sexual partners. Laboratory monitoring is not required for patients undergoing long-term suppressive therapy; however, the continued need for therapy should be reviewed annually. Length of time since last recurrence and potential benefits of continued suppression in preventing transmission to sexual partners are factors that can inform the decision to stop suppressive therapy."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_a_id_t31"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"904a17",
"children":[
"In primary infection, the viral cause and herpes simplex virus subtype should be confirmed by nucleic acid amplification testing using a swab obtained from the ulcer base."
]
},
{
"type":"keypoint",
"hlId":"42e93b",
"children":[
"Long-term suppressive therapy for recurrent herpes simplex virus infection may be preferred over self-start episodic therapy because of decreased risk of transmission to sexual partners."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_6_2",
"title":{
"__html":"Syphilis"
},
"titleNode":{
"type":"section-title",
"hlId":"fd36aa",
"children":[
"Syphilis"
]
},
"children":[
{
"type":"p",
"hlId":"f8cde5",
"children":[
"The incidence of primary and secondary syphilis has been increasing in the United States since 2000, and an alarming increase in congenital infections has been reported. The USPSTF recommends screening all pregnant women, nonpregnant adolescents, and adults at high risk of infection. Persons at risk include MSM and commercial sex workers and those with HIV infection, multiple sexual partners, and previous syphilis."
]
},
{
"type":"p",
"hlId":"5d1722",
"children":[
"Primary syphilis presents as a painless genital ulcer (chancre) with a raised regular border that demonstrates firm induration on palpation ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f22",
"wrapId":"8",
"children":[
"Figure 22"
]
}
]
},
")"
]
},
". Several chancres may be present and may occur in the oral cavity. Regional lymphadenopathy may be present. Serologic test results may be negative in early primary infection. Even without treatment, lesions heal spontaneously in 3 to 6 weeks."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_a_id_f22"
]
},
{
"type":"p",
"hlId":"108315",
"children":[
"The most common manifestation of secondary syphilis is rash. Various forms are described; involvement of the palms and soles is characteristic. In intertriginous areas, papules may coalesce to form condyloma lata ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f23",
"wrapId":"9",
"children":[
"Figure 23"
]
}
]
},
")"
]
},
". Mucous patches (superficial erosions on mucosal surfaces) may occur in the oral cavity and moist genital regions and are highly infectious ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f24",
"wrapId":"9",
"children":[
"Figure 24"
]
}
]
},
")"
]
},
". Prominent systemic symptoms and generalized lymphadenopathy are common. Uveitis and neurosyphilis (meningitis) can occur. Secondary syphilis manifestations can also resolve without treatment, followed by latent infection (a positive serologic test result without clinical manifestations). If latent infection is of less than 12 months' duration, it is termed early latent; if greater than 12 months' duration, it is late latent. Practically, these determinations can be made only if past serology results are available. Otherwise, patients are considered to have syphilis of unknown duration."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_a_id_f23",
"mk19_a_id_f24"
]
},
{
"type":"p",
"hlId":"567f2e",
"children":[
"Tertiary syphilis is uncommonly seen in the United States, although neurologic disease still occurs, including stroke, altered mental status, and auditory or ophthalmic abnormalities. Argyll Robertson pupil is an ophthalmologic finding in late neurosyphilis characterized by small and irregular pupils that do not constrict well to light but do constrict when focused on an object nearby (light-near dissociation). Spinal fluid should be examined in any patient with unexplained neurologic symptoms and serologic evidence of syphilis as well as in those who do not demonstrate an appropriate serologic response to syphilis treatment."
]
},
{
"type":"p",
"hlId":"275f3d",
"children":[
"Secondary and tertiary syphilis diagnosis relies on serologic testing. Many laboratories use the “reverse” serologic testing strategy, starting with an automated enzyme immunoassay followed by a nonspecific test (rapid plasma reagin or Venereal Disease Research Lab test). Patients with a positive enzyme immunoassay result but negative rapid plasma reagin or Venereal Disease Research Lab test result should have a second specific treponemal antibody test to confirm the result. Those with a confirmed positive result and no history of syphilis treatment should be offered treatment for syphilis of unknown duration."
]
},
{
"type":"p",
"hlId":"f6bd2b",
"children":[
"Syphilis treatment is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t32",
"wrapId":"10",
"children":[
"Table 32"
]
}
]
},
". Sexual partners of those with primary, secondary, or early latent syphilis exposed in the preceding 90 days should be treated regardless of serologic results."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_a_id_t32"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"eb36e7",
"children":[
"Primary syphilis presents as a painless genital ulcer (chancre) with a raised regular border that demonstrates firm induration on palpation; lesions heal spontaneously in 3 to 6 weeks even without treatment."
]
},
{
"type":"keypoint",
"hlId":"bab36b",
"children":[
"The most common manifestation of secondary syphilis is rash, with characteristic involvement of the palms and soles; in intertriginous areas, papules may coalesce to form condyloma lata, and mucous patches may occur in the oral cavity and moist genital regions and are highly infectious."
]
},
{
"type":"keypoint",
"hlId":"a6326a",
"children":[
"Secondary and tertiary syphilis diagnosis relies on serologic testing; patients with a positive enzyme immunoassay result and positive rapid plasma reagin or Venereal Disease Research Lab test result and no history of syphilis treatment should be offered treatment for syphilis of unknown duration."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_6_3",
"title":{
"__html":"Chancroid and Lymphogranuloma Venereum"
},
"titleNode":{
"type":"section-title",
"hlId":"18bb6e",
"children":[
"Chancroid and Lymphogranuloma Venereum"
]
},
"children":[
{
"type":"p",
"hlId":"ff3e52",
"children":[
"Except for proctitis or proctocolitis caused by the LGV serovars of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis,"
]
},
" these two STIs are rarely seen in the United States. The clinical presentation, evaluation, and treatment are outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_a_id_t33",
"wrapId":"11",
"children":[
"Table 33"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_a_id_t33"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_7",
"title":{
"__html":"Genital Warts"
},
"titleNode":{
"type":"section-title",
"hlId":"f9707d",
"children":[
"Genital Warts"
]
},
"children":[
{
"type":"p",
"hlId":"7a3352",
"children":[
"Genital warts have a variety of appearances, including papular or pedunculated lesions ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_a_id_f25",
"wrapId":"12",
"children":[
"Figure 25"
]
}
]
},
")"
]
},
". Larger, verrucous, exophytic lesions can occur. Most are asymptomatic; however, large lesions may cause irritation or pain depending on their location. Nononcogenic types of human papillomavirus (HPV) are responsible for most lesions. Specific testing for HPV is not recommended for diagnosis."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_a_id_f25"
]
},
{
"type":"p",
"hlId":"8cad85",
"children":[
"Warts often resolve without therapy, but treatment is indicated for symptomatic warts or psychological distress. Patients should be counseled that successful treatment might not eliminate the risk of transmission. Patient-applied therapies include imiquimod, podofilox, and sinecatechins; provider-administered therapies include trichloroacetic or bichloroacetic acid, cryotherapy with liquid nitrogen or cryoprobe, or surgical removal. No evidence indicates any recommended modality is superior. Ulcerated or pigmented warts and those that fail to respond to or worsen after therapy should be biopsied to exclude a cancerous lesion."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"80442b",
"children":[
"Nononcogenic types of human papillomavirus are responsible for most genital warts, which often resolve without therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_a_id_s9_8",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015;372:2039-48. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/25992748",
"target":"_blank"
},
"children":[
"PMID: 25992748"
]
},
" doi:10.1056/NEJMra1411426"
]
},
{
"type":"reference",
"children":[
"Gnann JW Jr, Whitley RJ. Clinical practice. Genital herpes. N Engl J Med. 2016;375:666-74. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27532832",
"target":"_blank"
},
"children":[
"PMID: 27532832"
]
},
" doi:10.1056/NEJMcp1603178"
]
},
{
"type":"reference",
"children":[
"Levy SB, Gunta J, Edemekong P. Screening for sexually transmitted diseases. Prim Care. 2019;46:157-173. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30704656",
"target":"_blank"
},
"children":[
"PMID: 30704656"
]
},
" doi:10.1016/j.pop.2018.10.013"
]
},
{
"type":"reference",
"children":[
"Lin JS, Eder ML, Bean SI. Screening for syphilis infection in pregnant women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320:918-925. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30193282",
"target":"_blank"
},
"children":[
"PMID: 30193282"
]
},
" doi:10.1001/jama.2018.7769"
]
},
{
"type":"reference",
"children":[
"St Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1911-1916. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33332296",
"target":"_blank"
},
"children":[
"PMID: 33332296"
]
},
" doi:10.15585/mmwr.mm6950a6"
]
},
{
"type":"reference",
"children":[
"US Preventive Services Task Force, Krist AH, Davidson KW, et al. Behavioral counseling interventions to prevent sexually transmitted infections: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(7):674-681. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32809008",
"target":"_blank"
},
"children":[
"PMID: 32809008"
]
},
" doi:10.1001/jama.2020.13095"
]
},
{
"type":"reference",
"children":[
"Williamson DA, Chen MY. Emerging and reemerging sexually transmitted infections. N Engl J Med. 2020;382:2023-2032. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/32433838",
"target":"_blank"
},
"children":[
"PMID: 32433838"
]
},
" doi:10.1056/NEJMra1907194"
]
},
{
"type":"reference",
"children":[
"Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1-187. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34292926",
"target":"_blank"
},
"children":[
"PMID: 34292926"
]
},
" doi:10.15585/mmwr.rr7004a1"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_a_id_t30":{
"id":"mk19_a_id_t30",
"number":30,
"bookId":"id",
"title":{
"__html":"Treatment of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> Infections and Their Complications"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"80abc3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 30. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t30"
}
]
},
"Treatment of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria gonorrhoeae"
]
},
" Infections and Their Complications"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4099c",
"class":"col hd l",
"children":[
"Clinical Syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae9124",
"class":"col hd l",
"children":[
"Preferred Regimen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f870f",
"class":"col hd l",
"children":[
"Alternate Regimen"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06733c",
"class":"cell txt l",
"children":[
"Nongonococcal cervicitis and urethritis (general empiric therapy)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d7804",
"class":"cell txt l",
"children":[
"Doxycycline",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
", 100 mg PO twice daily for 7 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"85cde8",
"class":"cell txt l",
"children":[
"Azithromycin, 1 g PO single dose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5a0a51",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia"
]
},
" cervicitis, urethritis, or proctitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c08bd5",
"class":"cell txt l",
"children":[
"Doxycycline",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
", 100 mg PO twice daily for 7 d"
]
},
" ",
{
"type":"p",
"hlId":"2087a5",
"class":"cell txt l",
"children":[
"During pregnancy: Azithromycin, 1 g PO single dose, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" amoxicillin 500 mg PO three times daily for 7 d "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ae920",
"class":"cell txt l",
"children":[
"Azithromycin, 1 g PO single dose, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" levofloxacin, 500 mg PO daily for 7 d"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c9f48",
"class":"cell txt l",
"children":[
"Gonococcal cervicitis, urethritis, or proctitis and pharyngeal infection",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b,c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5beb4",
"class":"cell txt l",
"children":[
"Ceftriaxone, 500 mg IM single dose (1 g IM single dose for persons ≥150 kg [300 lbs]), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
}
]
},
" ",
{
"type":"p",
"hlId":"40eefb",
"class":"cell txt l",
"children":[
"doxycycline",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
", 100 mg PO twice daily for 7 d; or, if pregnant, azithromycin, 1 g PO single dose (if concomitant chlamydial infection is not ruled out)"
]
},
" ",
{
"type":"p",
"hlId":"28fe83",
"class":"cell txt l",
"children":[
"Test for cure 2 weeks after treatment for pharyngeal gonorrhea"
]
},
" ",
{
"type":"p",
"hlId":"d5cc12",
"class":"cell txt l",
"children":[
"Retest 3 months after treatment "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"deb647",
"class":"cell txt l",
"children":[
"In patients allergic to cephalosporins, gentamicin, 240 mg IM single dose, plus azithromycin, 2 g PO single dose"
]
},
" ",
{
"type":"p",
"hlId":"992254",
"class":"cell txt l",
"children":[
"Cefixime",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
", 800 mg PO single dose, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
}
]
},
" ",
{
"type":"p",
"hlId":"d05e2e",
"class":"cell txt l",
"children":[
"doxycycline, 100 mg PO twice daily for 7 d, or, if pregnant, azithromycin 1 g PO single dose (if concomitant chlamydial infection is not ruled out)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a11bdc",
"class":"cell txt l",
"children":[
"Disseminated gonococcal infection",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e,f"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6e045",
"class":"cell txt l",
"children":[
"Ceftriaxone, 1 g IM or IV every 24 h, plus doxycycline",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
", 100 mg PO twice daily for 7 d (if concomitant chlamydial infection is not ruled out)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8f89f",
"class":"cell txt l",
"children":[
"Cefotaxime, 1 g IV every 8 h, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" ceftizoxime",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
},
", 1 g IV every 8 h, plus doxycycline, 100 mg PO twice daily for 7 d (if concomitant chlamydial infection is not ruled out) "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"033733",
"class":"cell txt l",
"children":[
"Pelvic inflammatory disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63e4b2",
"class":"cell txt li",
"children":[
"Parenteral therapy",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f2647",
"class":"cell txt l",
"children":[
"Ceftriaxone, 1 g IV every 24 hours, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" doxycycline, 100 mg PO or IV every 12 hours, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" metronidazole, 500 mg PO or IV every 12 hours"
]
},
" ",
{
"type":"p",
"hlId":"1d00e7",
"class":"cell txt l",
"children":[
"OR"
]
},
" ",
{
"type":"p",
"hlId":"25c174",
"class":"cell txt l",
"children":[
"Cefotetan, 2 g IV every 12 h, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" doxycycline, 100 mg PO or IV every 12 h"
]
},
" ",
{
"type":"p",
"hlId":"1d00e7",
"class":"cell txt l",
"children":[
"OR"
]
},
" ",
{
"type":"p",
"hlId":"b44469",
"class":"cell txt l",
"children":[
"Cefoxitin, 2 g IV every 6 h, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" doxycycline, 100 mg PO or IV every 12 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"04d3c2",
"class":"cell txt l",
"children":[
"Ampicillin-sulbactam, 3 g IV every 6 h, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" doxycycline, 100 mg IV or PO every 12 h"
]
},
" ",
{
"type":"p",
"hlId":"1d00e7",
"class":"cell txt l",
"children":[
"OR"
]
},
" ",
{
"type":"p",
"hlId":"e680ce",
"class":"cell txt l",
"children":[
"Clindamycin, 900 mg IV every 8 h, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" gentamicin, 2 mg/kg IM or IV loading dose followed by 1.5 mg/kg IV every 8 hours or a single daily dose of 3-5 mg/kg/d"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"672bb5",
"class":"cell txt li",
"children":[
"Oral/IM therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"633e44",
"class":"cell txt l",
"children":[
"Ceftriaxone, 500 mg IM single dose (1 g for persons ≥150 kg [300 lbs]), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" doxycycline, 100 mg PO twice daily for 14 days, with metronidazole, 500 mg PO twice daily for 14 days"
]
},
" ",
{
"type":"p",
"hlId":"1d00e7",
"class":"cell txt l",
"children":[
"OR"
]
},
" ",
{
"type":"p",
"hlId":"3551a0",
"class":"cell txt l",
"children":[
"Cefoxitin, 2 g IM single dose, and probenecid, 1 g PO, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" doxycycline, 100 mg PO twice daily for 14 days, with metronidazole, 500 mg PO twice daily for 14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f6aace",
"class":"cell txt l",
"children":[
"Epididymitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5554c2",
"class":"cell txt l",
"children":[
"Ceftriaxone, 500 mg IM single dose, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" doxycycline, 100 mg PO twice daily for 10 d if infection most likely caused by chlamydia/gonorrhea"
]
},
" ",
{
"type":"p",
"hlId":"1d00e7",
"class":"cell txt l",
"children":[
"OR"
]
},
" ",
{
"type":"p",
"hlId":"875f76",
"class":"cell txt l",
"children":[
"Ceftriaxone, 500 mg IM single dose, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"plus"
]
},
" levofloxacin, 500 mg PO once daily for 10 d if infection might be caused by chlamydia/gonorrhea or enteric organisms (insertive anal intercourse)"
]
},
" ",
{
"type":"p",
"hlId":"1d00e7",
"class":"cell txt l",
"children":[
"OR"
]
},
" ",
{
"type":"p",
"hlId":"ee4507",
"class":"cell txt l",
"children":[
"Levofloxacin, 500 mg PO once daily for 10 d if infection most likely caused by enteric organisms only (gonorrhea has been ruled out)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IM = intramuscularly; IV = intravenously; LGV = lymphogranuloma venereum; PO = orally."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Doxycyline should be avoided in pregnant patients."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Treatment for possible chlamydial infection is recommended for all patients diagnosed with gonorrhea. Currently recommended treatment regimens for gonorrhea provide this coverage."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"No reliable alternative treatments are available for pharyngeal gonorrhea. For persons with a history of a β-lactam allergy, a thorough assessment of the reaction is recommended."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Cefixime should be used only if ceftriaxone is unavailable because oral cephalosporin resistance to ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"N. gonorrhoeae"
]
},
" has been increasingly reported."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"For arthritis-dermatitis syndrome, parenteral therapy should be used until 24 to 48 hours after substantial clinical improvement and then switched to an oral therapy based on susceptibility results for a total of 7 to 10 days of treatment."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
"Meningitis and endocarditis require ceftriaxone, 1 to 2 g IV every 24 h, plus doxycycline, 100 mg PO twice daily for 7 d if chlamydia infection has not been ruled out. Parenteral therapy is required for the entire course of treatment for meningitis (10 to 14 days) and endocarditis (at least 28 days)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
},
"Not available in the United States."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
},
"Patients can be switched to oral therapy within 24 to 48 hours of clinical improvement using doxycycline, 100 mg PO twice daily, with or without metronidazole, 500 mg PO twice daily, to complete a total of 14 days of therapy."
]
]
},
"mk19_a_id_t31":{
"id":"mk19_a_id_t31",
"number":31,
"bookId":"id",
"title":{
"__html":"Treatment of Herpes Simplex Virus Genital Infections"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"08dcd7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 31. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t31"
}
]
},
"Treatment of Herpes Simplex Virus Genital Infections"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4099c",
"class":"col hd l",
"children":[
"Clinical Syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2594be",
"class":"col hd l",
"children":[
"Recommended Regimen",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab3a04",
"class":"cell txt l",
"children":[
"Primary infection",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70155a",
"class":"cell txt l",
"children":[
"Acyclovir, 400 mg three times daily, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" acyclovir, 200 mg five times daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" famciclovir, 250 mg three times daily, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" valacyclovir, 1 g twice daily; all regimens for 7-10 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"76a512",
"class":"cell txt l",
"children":[
"Episodic treatment for recurrent infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"191076",
"class":"cell txt l",
"children":[
"Acyclovir, 400 mg three times daily for 5 days",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" acyclovir, 800 mg twice daily for 5 days, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" acyclovir, 800 mg three times daily for 2 days, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" famciclovir, 125 mg twice daily for 5 days, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" famciclovir, 1 g twice daily for 1 day, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" famciclovir, 500 mg once followed by 250 mg twice daily for 2 days, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" valacyclovir, 500 mg twice daily for 3 days, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" valacyclovir, 1 g once daily for 5 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"807c96",
"class":"cell txt l",
"children":[
"Suppressive therapy for recurrent infection"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e93704",
"class":"cell txt l",
"children":[
"Acyclovir, 400 mg twice daily, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" famciclovir, 250 mg twice daily, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" valacyclovir, 500 mg daily",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" valacyclovir, 1 g daily"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"All regimens are given orally; topical preparations are not recommended for treatment of genital herpes simplex virus."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Therapy can be extended if healing is incomplete after 10 days of treatment."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"According to 2021 CDC guidelines, these acyclovir dosages are effective but are not recommended because of dosing frequency."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"The 500-mg dose of valacyclovir may be less effective than the 1-g dose in patients who have very frequent recurrences (≥10 episodes per year)."
]
]
},
"mk19_a_id_t32":{
"id":"mk19_a_id_t32",
"number":32,
"bookId":"id",
"title":{
"__html":"Treatment of Syphilis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"14df80",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 32. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t32"
}
]
},
"Treatment of Syphilis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64c6da",
"class":"col hd l",
"children":[
"Stage"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2594be",
"class":"col hd l",
"children":[
"Recommended Regimen",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c546d8",
"class":"col hd l",
"children":[
"Alternate Regimen for Penicillin-Allergic Patients"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4c6b6",
"class":"cell txt l",
"children":[
"Primary and secondary"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42f938",
"class":"cell txt l",
"children":[
"Benzathine penicillin G, 2.4 million units IM single dose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d4203",
"class":"cell txt l",
"children":[
"Doxycycline, 100 mg PO twice daily, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" tetracycline, 500 mg PO four times daily, for 14 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"310029",
"class":"cell txt l",
"children":[
"Early latent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"42f938",
"class":"cell txt l",
"children":[
"Benzathine penicillin G, 2.4 million units IM single dose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d4203",
"class":"cell txt l",
"children":[
"Doxycycline, 100 mg PO twice daily, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" tetracycline, 500 mg PO four times daily, for 14 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"768369",
"class":"cell txt l",
"children":[
"Late latent or syphilis of unknown duration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fad061",
"class":"cell txt l",
"children":[
"Benzathine penicillin G, 2.4 million units IM at 1-week intervals for 3 doses"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"802d04",
"class":"cell txt l",
"children":[
"Doxycycline, 100 mg PO twice daily, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" tetracycline, 500 mg PO four times daily, for 28 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d667b0",
"class":"cell txt l",
"children":[
"Neurosyphilis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6d8c3",
"class":"cell txt l",
"children":[
"Aqueous crystalline penicillin G, 18-24 million units daily given as 3-4 million units IV every 4 hours or by continuous infusion for 10-14 days, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" procaine penicillin, 2.4 million units IM daily, plus probenecid, 500 mg PO four times daily, both for 10-14 days"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4ec147",
"class":"cell txt l",
"children":[
"Ceftriaxone, 2 g IM or IV daily for 10-14 days",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IM = intramuscularly; IV = intravenously; PO = orally."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Penicillin is the only effective antimicrobial agent for treatment of syphilis at any stage in pregnancy; therefore, pregnant penicillin-allergic patients should be desensitized and treated with the appropriate penicillin regimen as outlined above."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Limited data are available to support the use of this alternate regimen, and the possibility of cross-reaction in penicillin-allergic patients must be considered. In patients who cannot take ceftriaxone, penicillin desensitization is recommended."
]
]
},
"mk19_a_id_t33":{
"id":"mk19_a_id_t33",
"number":33,
"bookId":"id",
"title":{
"__html":"Clinical Presentation, Diagnosis, and Treatment of Chancroid and Lymphogranuloma Venereum"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"6edb36",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 33. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t33"
}
]
},
"Clinical Presentation, Diagnosis, and Treatment of Chancroid and Lymphogranuloma Venereum"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"851ee1",
"class":"col hd l",
"children":[
"Clinical Entity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5d0917",
"class":"col hd l",
"children":[
"Causative Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c7bc3f",
"class":"col hd l",
"children":[
"Presentation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"523223",
"class":"col hd l",
"children":[
"Diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"390eeb",
"class":"col hd l",
"children":[
"Recommended Regimen"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a0a4f3",
"class":"cell txt l",
"children":[
"Chancroid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1a841",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Haemophilus ducreyi"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"685f68",
"class":"cell txt l",
"children":[
"Painful genital ulcer; tender inguinal lymph nodes, which often suppurate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"272c76",
"class":"cell txt l",
"children":[
"Culture is difficult; consider diagnosis if painful ulcer with tender and suppurative regional lymphadenopathy, no evidence of syphilis by dark-field examination or serology, and negative HSV PCR or HSV culture"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a717b",
"class":"cell txt l",
"children":[
"Azithromycin, 1 g PO single dose, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" ceftriaxone, 250 mg IM single dose, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" ciprofloxacin, 500 mg PO twice daily for 3 days, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" erythromycin base, 500 mg PO three times daily for 7 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b25592",
"class":"cell txt l",
"children":[
"LGV"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb97b1",
"class":"cell txt l",
"children":[
"L1, L2, and L3 serovars of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Chlamydia trachomatis"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71ef9c",
"class":"cell txt l",
"children":[
"Painless genital papule or ulcer with unilateral tender inguinal lymphadenopathy; proctitis, proctocolitis in MSM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"61429d",
"class":"cell txt l",
"children":[
"NAAT for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
"; does not distinguish the serovars, so diagnosis is made based on clinical and epidemiologic findings"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d1bbb0",
"class":"cell txt l",
"children":[
"Doxycycline",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
", 100 mg PO twice daily for 21 days (preferred), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" azithromycin 1 g PO once weekly for 3 weeks",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
" (alternate), ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"or"
]
},
" erythromycin base, 500 mg PO four times daily for 21 days (alternate)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"HSV = herpes simplex virus; IM = intramuscularly; LGV = lymphogranuloma venereum; MSM = men who have sex with men; NAAT = nucleic acid amplification test; PCR = polymerase chain reaction; PO = orally."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Doxycyline should be avoided or used with caution in pregnant patients."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Because this regimen has not been validated, a test of cure with ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"C. trachomatis"
]
},
" NAAT 4 weeks after treatment completion can be considered."
]
]
}
}
}